Sign in Subscribe

FDA Grants Breakthrough Status to Zovegalisib for Advanced Breast Cancer

Relay Therapeutics' (RLAY) zovegalisib receives FDA Breakthrough Therapy designation for treating PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor treatment.

FDA Grants Breakthrough Status to Zovegalisib for Advanced Breast Cancer
Photo by National Cancer Institute on Unsplash
Already have an account? Sign in.